RxDoctor Payments Data

Kevin Basralian, MD

Urology · Hackensack, NJNPI 1851392252

Payments from drug & device makers

$8,126in general payments, 2019–2025

Across 72 payments — averaging $112.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$3K
  • Procept Biorobotics Corporation$1K
  • Boston Scientific$924
  • EDAP Technomed Inc$698
  • Johnson & Johnson$361
  • Profound Medical Corp.$311
  • plus $1K from 15 others

What the payments were for

  • Travel & lodging$1,65920%
  • Food & beverage$6,31678%
  • Education$1302%
  • Entertainment$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,126 in reported general payments places this provider in the 75th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$128,316
Medicare patients
372
Services billed
1,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron19$22,072
Tamsulosin Hcl380$6,866
Finasteride176$2,929
Oxybutynin Chloride ErOxybutynin Chloride59$2,207
Silodosin14$1,709
Alfuzosin Hcl ErAlfuzosin Hcl42$1,338
Dutasteride27$888
Terazosin Hcl16$535
Bicalutamide13$405
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$282
NitrofurantoinNitrofurantoin Macrocrystal12$253
Famciclovir11$186
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim41$154
Cephalexin20$86
Acyclovir11$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$57$22,07219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 401 urology providers in New Jersey.

Other urology in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →